Xenetic Biosciences (XBIO) Stock Price, News & Analysis

Company Overview

Xenetic Biosciences, Inc. is a clinical-stage biotechnology company focused on developing targeted therapeutics for cancer and other serious diseases. The company’s research and development activities center on immuno-oncology, cell therapy, and proprietary drug-development technologies intended to improve the effectiveness, safety, or delivery of existing and emerging treatments.

Xenetic’s technology portfolio has included XCART, an investigational personalized cell-therapy platform designed to use a patient’s own immune cells to target tumor-associated antigens. The company has also advanced oncology drug candidates and related research programs, including XBIO-101, an investigational compound studied for potential use in cancer treatment. These programs remain subject to clinical testing and regulatory review.

Based in the United States, Xenetic Biosciences has historically pursued development through internal research, clinical programs, and collaborations with biotechnology and pharmaceutical organizations. Its products are investigational and are not broadly marketed or approved for commercial use unless otherwise authorized by applicable regulators.

Key Stats

• Today's Range: $2.11 to $2.33
• 50-Day Range: $2.19 to $4.67
• 52-Week Range: $1.87 to $13.93
• Volume: 43,201 shs
• Average Volume: 43,402 shs
• Market Capitalization: $5.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Xenetic Biosciences Stock Analysis - MarketRank™

Xenetic Biosciences scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Xenetic Biosciences has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Xenetic Biosciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Xenetic Biosciences is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Xenetic Biosciences is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Xenetic Biosciences has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.06% of the float of Xenetic Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Xenetic Biosciences has a short interest ratio ("days to cover") of 0.45, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Xenetic Biosciences has recently increased by 10.56%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Xenetic Biosciences does not currently pay a dividend.

Dividend Growth

Xenetic Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: N/A

News Sentiment

Xenetic Biosciences has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Xenetic Biosciences this week, compared to 1 article on an average week.

Search Interest

Only 2 people have searched for XBIO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added Xenetic Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Xenetic Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.60% of the stock of Xenetic Biosciences is held by insiders.

Percentage Held by Institutions

15.12% of the stock of Xenetic Biosciences is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/02/2026
• Next Earnings (Estimated): 11/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:XBIO
• CIK: 1534525
• Web: www.xeneticbio.com
• Phone: 781-778-7720
• Fax: N/A
• Employees: 2
• Year Founded: 2011

Profitability

• EPS (Trailing Twelve Months): ($1.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$2.68 million
• Net Margins: -75.90%
• Pretax Margin: -75.90%
• Return on Equity: -40.62%
• Return on Assets: -34.97%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.43
• Quick Ratio: 7.43

Sales & Book Value

• Annual Sales: $2.98 million
• Price / Sales: 1.72
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.23 per share
• Price / Book: 0.69

Miscellaneous

• Outstanding Shares: 2,290,000
• Free Float: 2,117,000
• Market Cap: $5.13 million
• Optionable: Not Optionable
• Beta: 2.20